← Leaderboards
Amy C Degnim
Mayo Clinic Rochester
$9,208,153
Attributed
$14,884,305
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,884,305 · 7
By mechanism
R01$13,293,735 · 4
P50$1,411,645 · 2
P30$178,925 · 1
Top collaborators
- Mark E Sherman14 shared
- Derek C Radisky12 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Stephen B Kritchevsky$48,894,177
- Scott H Kaufmann$29,002,745
- Howard J Rosen$46,265,858
- Adam L Boxer$75,127,044
- Evanthia Galanis$13,573,895
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanBreast DiseasesBiopsyMalignant Breast NeoplasmPreventionBenignCohortBiological MarkersInnovationClinicBreast Cancer Risk FactorFutureMammary Gland ParenchymaDiagnosisBreast Cancer PreventionIncidenceMalignant NeoplasmsSamplingNano-StringCellsBasePathway InteractionsBreast BiopsyBreast
Grant awards (28)
Project 3$267,961
P50 · FY2025 · CA · contact PI
Advanced Clinical Trials and Translational Sciences$178,925
P30 · FY2025 · CA · contact PI
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$637,457
R01 · FY2024 · CA · contact PI
Involution-based biomarkers of breast cancer risk$473,716
R01 · FY2024 · CA
Involution-based biomarkers of breast cancer risk$141,218
R01 · FY2024 · CA
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$890,696
R01 · FY2023 · CA · contact PI
Project 3$653,611
P50 · FY2023 · CA · contact PI
Involution-based biomarkers of breast cancer risk$486,563
R01 · FY2023 · CA
Involution-based biomarkers of breast cancer risk$148,650
R01 · FY2023 · CA
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$861,161
R01 · FY2022 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$639,236
R01 · FY2022 · CA
Project 3$490,073
P50 · FY2022 · CA · contact PI
Involution-based biomarkers of breast cancer risk$488,556
R01 · FY2022 · CA
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$887,829
R01 · FY2021 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$637,416
R01 · FY2021 · CA
Involution-based biomarkers of breast cancer risk$507,487
R01 · FY2021 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$102,875
R01 · FY2021 · CA
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia$884,460
R01 · FY2020 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$721,306
R01 · FY2020 · CA
Involution-based biomarkers of breast cancer risk$554,827
R01 · FY2020 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$619,727
R01 · FY2019 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$95,085
R01 · FY2019 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$640,367
R01 · FY2018 · CA
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a$584,884
R01 · FY2018 · CA · contact PI
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a$583,377
R01 · FY2017 · CA · contact PI
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a$603,871
R01 · FY2016 · CA · contact PI
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a$561,339
R01 · FY2015 · CA · contact PI
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a$541,632
R01 · FY2014 · CA · contact PI